Myriad Genetics/$MYGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Myriad Genetics
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Ticker
$MYGN
Sector
Primary listing
Employees
2,700
Headquarters
Website
Myriad Genetics Metrics
BasicAdvanced
$758M
-
-$4.33
1.98
-
Price and volume
Market cap
$758M
Beta
1.98
52-week high
$21.95
52-week low
$3.76
Average daily volume
1.2M
Financial strength
Current ratio
1.422
Quick ratio
1.058
Long term debt to equity
22.211
Total debt to equity
39.835
Interest coverage (TTM)
-20.18%
Profitability
EBITDA (TTM)
-17.6
Gross margin (TTM)
70.43%
Net profit margin (TTM)
-47.45%
Operating margin (TTM)
-9.21%
Effective tax rate (TTM)
5.99%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-5.44%
Return on equity (TTM)
-70.03%
Valuation
Price to revenue (TTM)
0.895
Price to book
1.96
Price to tangible book (TTM)
4.56
Price to free cash flow (TTM)
-14.906
Free cash flow yield (TTM)
-6.71%
Free cash flow per share (TTM)
-0.547
Growth
Revenue change (TTM)
3.83%
Earnings per share change (TTM)
143.08%
3-year revenue growth (CAGR)
7.40%
3-year earnings per share growth (CAGR)
169.75%
What the Analysts think about Myriad Genetics
Analyst ratings (Buy, Hold, Sell) for Myriad Genetics stock.
Bulls say / Bears say
Hereditary cancer testing revenue grew 9% year-over-year in Q2 2025, with testing volume up 10% and MyRisk with RiskScore volume up 14%, highlighting strength in Myriad’s core oncology segment (GlobeNewswire).
Gross margin expanded by 160 basis points to 71.2% in Q2 2025, driven by favorable product mix, improved average revenue per test, and greater laboratory efficiencies (GlobeNewswire).
Management raised full-year 2025 revenue guidance to $818 million–$828 million from $807 million–$823 million, reflecting confidence in ongoing business momentum and pricing trends (AP News).
Myriad reported a GAAP net loss of $330.5 million in Q2 2025, driven by a non-cash impairment charge of $316.7 million due to a decline in its market capitalization, significantly weighing on profitability (AP News).
Pharmacogenomics revenue (GeneSight) declined 12% year-over-year to $37.8 million in Q2 2025, with test volumes growing only 5%, reflecting ongoing headwinds from UnitedHealthcare’s coverage discontinuation (GlobeNewswire).
Overall Q2 2025 revenue grew by just 1% year-over-year to $213.1 million, underscoring the company’s struggle to accelerate top-line growth despite favorable adjustments for headwinds (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Myriad Genetics Financial Performance
Revenues and expenses
Myriad Genetics Earnings Performance
Company profitability
Myriad Genetics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Myriad Genetics stock?
Myriad Genetics (MYGN) has a market cap of $758M as of October 26, 2025.
What is the P/E ratio for Myriad Genetics stock?
The price to earnings (P/E) ratio for Myriad Genetics (MYGN) stock is 0 as of October 26, 2025.
Does Myriad Genetics stock pay dividends?
No, Myriad Genetics (MYGN) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Myriad Genetics dividend payment date?
Myriad Genetics (MYGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Myriad Genetics?
Myriad Genetics (MYGN) has a beta rating of 1.98. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.